Test Price
2,200 AED✅ Home Collection Available
Bacterial Pneumonia Multiplex RNA Detection & Differentiation Panel (7-Pathogen PCR) in UAE | 2200 AED | DHA Licensed
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139). This 7-pathogen Real-Time PCR panel delivers definitive RNA-based detection and differentiation of S. pneumoniae, H. influenzae, N. meningitidis, C. pneumoniae, M. pneumoniae, L. pneumophila, and B. pertussis with clinical-grade precision.
Collection Protocol: Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. Nasopharyngeal swab, blood, CSF, bronchial lavage, and bronchial swab specimens are collected by DHA-licensed professionals in a controlled clinical setting.
Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation by qualified clinical advisors. Direct Billing Insurance Verification via WhatsApp: +971 54 548 8731.
Turnaround Time: Preliminary phone result within 36 hours; official DHA-compliant digital report by the 4th working day via encrypted email.
Test Overview & Methodology
The Bacterial Pneumonia Multiplex RNA Detection & Differentiation Panel is a high-specificity, qualitative Real-Time PCR (qPCR) assay designed for the simultaneous detection and species-level differentiation of seven clinically significant bacterial respiratory pathogens. This panel is indispensable for guiding targeted antimicrobial therapy, reducing empiric broad-spectrum antibiotic use, and rapidly confirming or excluding atypical and fastidious organisms that are undetectable by conventional sputum culture — including Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila.
The assay employs RNA-targeted amplification with whole genome sequencing cross-validation, enabling detection even after antibiotic therapy has commenced. This methodological advantage ensures that patients who have received prior antimicrobial treatment still obtain an accurate etiologic diagnosis, directly supporting antimicrobial stewardship programs across UAE healthcare facilities.
| Feature | Our Test (qPCR Multiplex Panel) | Conventional Sputum Culture |
|---|---|---|
| Precision / Methodology | Real-Time PCR with Whole Genome Sequencing (WGS) cross-validation; RNA-targeted detection | Gram stain and agar culture; limited sensitivity for fastidious organisms |
| Speed | 36 hours (phone) / 48 hours (email) — 4th working day official report | 48–72 hours preliminary; 5–7 days final identification |
| Atypical Pathogen Coverage | Full: M. pneumoniae, C. pneumoniae, L. pneumophila, B. pertussis included | Minimal; requires separate serology or specialized media |
| Antibiotic Interference | Minimal: PCR detects RNA regardless of prior antibiotic exposure | Significant; prior antibiotics frequently yield false-negative cultures |
| Sample Types Accepted | Nasopharyngeal swab, blood, CSF, bronchial swab, bronchial lavage, nasopharyngeal secretions | Primarily sputum; invasive samples require separate workflows |
Physician Insight & Safety Protocols
A Note from Dr. Ajay Singh (DHA Registration ID: 36234132): "This multiplex PCR panel represents a significant advancement in respiratory diagnostics, enabling pathogen-specific treatment decisions within 36 hours of specimen collection. However, a positive RNA detection must always be correlated with the patient's clinical presentation, chest imaging findings, and inflammatory biomarkers such as procalcitonin and C-reactive protein. No single laboratory test replaces comprehensive clinical judgment; co-infections and asymptomatic colonization can occur, particularly in immunocompromised or elderly patients. I advise every clinician and patient to interpret these results as one component of a holistic diagnostic assessment, never in isolation."
Medication Advisory
Do not discontinue any prescribed medication — including antibiotics, corticosteroids, or bronchodilators — without consulting your treating physician. A negative PCR result does not exclude all causes of respiratory illness, and premature cessation of therapy may lead to clinical deterioration, treatment failure, or increased antimicrobial resistance.
Exclusion Criteria & Emergency Red Flags
Do not rely solely on outpatient testing if any of the following are present. Proceed immediately to the nearest Emergency Department:
- Respiratory rate ≥ 30 breaths per minute in adults or severe dyspnea at rest
- Oxygen saturation (SpO₂) persistently below 92% on room air
- Systolic blood pressure below 90 mmHg or signs of septic shock (cold extremities, altered mental status, mottled skin)
- Acute confusion, new-onset seizure, or meningeal signs (neck stiffness, photophobia — especially relevant when N. meningitidis is suspected)
- Hemoptysis exceeding 50 mL in 24 hours
- Infants under 3 months of age with fever ≥ 38.0°C and respiratory distress
Hospital Collection Requirement: All specimen collection for this panel is conducted within accredited hospital facilities. CSF collection requires a licensed neurologist or intensivist. Patients under 12 years require parent or guardian presence and signed minor consent in accordance with UAE Federal Law. Home phlebotomy is not available for this test owing to the invasive nature of CSF collection and the need for controlled clinical oversight.
Patient FAQ & Clinical Guidance
1. What is the turnaround time for my Bacterial Pneumonia Multiplex PCR results, and how should I interpret a detected result?
You will receive a preliminary phone result within 36 hours of specimen receipt at our ISO-accredited laboratory, followed by an official encrypted email report on the 4th working day. A detected result indicates the presence of bacterial RNA from one or more of the seven targeted pathogens, confirming active infection that requires correlation with your clinical symptoms by your referring physician. Your doctor will interpret the specific pathogen identified alongside your chest imaging, inflammatory markers, and physical examination to prescribe the narrowest effective antimicrobial agent. This precision approach reduces side effects, shortens recovery time, and supports antimicrobial stewardship.
2. How does this multiplex PCR panel differ from a standard sputum culture that my doctor might order first?
This multiplex PCR panel detects bacterial RNA directly with 99.9% sensitivity even after antibiotic therapy has commenced, whereas sputum culture requires viable organisms to grow over 48 to 120 hours and frequently fails to identify atypical pathogens such as Mycoplasma pneumoniae or Legionella pneumophila that do not grow on standard media. Additionally, PCR differentiates all seven pathogens simultaneously in a single run, accelerating the transition from empiric to definitive therapy, while culture often demands multiple separate tests with significantly longer turnaround times and lower detection yields for fastidious organisms.
3. Is this test approved under UAE healthcare regulations, and can I use my insurance to cover the 2200 AED cost?
Yes, this panel is fully compliant with Federal Decree-Law No. 4 of 2016 on Medical Liability and all applicable DHA diagnostic service standards. It is processed in our ISO 9001:2015 certified facility (Cert: INT/EGQ/2509DA/3139) licensed by DHA under facility license number 1143. We offer direct billing verification with major UAE insurers via WhatsApp at +971 54 548 8731 prior to your appointment. The 2200 AED fee covers the complete 7-pathogen multiplex PCR, specimen collection consumables, cold-chain logistics, board-certified clinical interpretation, and the post-test telephonic consultation — ensuring full transparency with no hidden charges.
4. Why is specimen collection restricted to hospital settings for this test?
This panel accepts multiple specimen types, including cerebrospinal fluid (CSF) which requires a lumbar puncture — an invasive procedure that must be performed by a licensed physician in a controlled hospital environment to ensure patient safety and sterile technique. Additionally, bronchial lavage and bronchial swab collections require specialist oversight. To maintain uniform safety standards and clinical governance across all collection scenarios, all specimens for this panel are collected exclusively within accredited hospital facilities. This policy eliminates variability in collection quality and ensures immediate access to emergency care if any adverse event occurs during the procedure.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance: This diagnostic service operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient data is encrypted in transit and at rest, stored within UAE-based servers, and accessed only by authorized clinical personnel under strict data governance protocols. Clinical safety and patient consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring that every specimen collection and diagnostic result is handled with the highest standards of medical accountability and patient rights protection.
Laboratory Credentials: DHA Facility License Number: 1143. ISO 9001:2015 Certification: INT/EGQ/2509DA/3139. All clinical personnel hold current DHA registration and licensure. Report any concerns to the DHA hotline or contact our patient advocacy team via WhatsApp at +971 54 548 8731.
Clinical & Logistical Metadata
| Test Name | Bacterial Pneumonia Multiplex RNA Detection & Differentiation Panel (7-Pathogen PCR) |
| Price (AED) | 2200 AED (all-inclusive, no hidden charges) |
| Turnaround Time | 36 hours preliminary phone result; official report by 4th working day via encrypted email |
| Sample Type / Matrix | Nasopharyngeal swab (flocked nylon, universal transport medium), blood (venous), CSF, bronchial swab, bronchial lavage, nasopharyngeal secretions |
| Methodology Used | Real-Time PCR (qPCR) with RNA-targeted amplification and Whole Genome Sequencing (WGS) cross-validation for pathogen differentiation |
| ICD-10-CM Code | J15.9 (Bacterial pneumonia, unspecified), J15.7 (Pneumonia due to Mycoplasma pneumoniae), A37.90 (Whooping cough due to Bordetella pertussis) |
| LOINC Code | 82159-5 (Respiratory Pathogen RNA Panel) |
| DHA Facility License & Laboratory Address | License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians